Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States

Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States

Abstract The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an economic model to estimate health outcomes, cost differ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Douglas Dietrich, Nancy Reau, Aijaz Ahmed, Rob Blissett, Adam Igloi-Nagy, Alon Yehoshua
Format:	Article
Language:	English
Published:	BMC 2025-06-01
Series:	Cost Effectiveness and Resource Allocation
Subjects:	Hepatitis C virus Cost-utility model Testing and treatment United States
Online Access:	https://doi.org/10.1186/s12962-025-00622-y
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
by: Gyeongseon Shin, et al.
Published: (2025-01-01)

Cost-effectiveness of tenofovir disoproxil fumarate prophylaxis for perinatal hepatitis B virus prevention in Ethiopia: a decision analytical modeling
by: Abdi Gari Negasa, et al.
Published: (2025-04-01)

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
by: Eun Sun Jang
Published: (2025-04-01)

Exploring the patient experience of chronic hepatitis D (CHD) and assessment of content validity of the Hepatitis Quality of Life Questionnaire and (HQLQv2) and the Fatigue Severity Scale (FSS)
by: Pietro Lampertico, et al.
Published: (2025-07-01)

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests
by: Huiyul Park, et al.
Published: (2025-07-01)

Can governance mechanisms minimize agency costs?
by: Linda Linda, et al.
Published: (2024-06-01)

Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses
by: José Ramón Lago-Quinteiro, et al.
Published: (2025-12-01)

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
by: Meiyu Wu, et al.
Published: (2025-04-01)

Comparative Evaluation of Simplified and Modified Histologic Criteria in the Diagnosis of Chronic Autoimmune Hepatitis
by: Mohammad H. Sanei, et al.
Published: (2025-03-01)

Residential Irrigation Water Costs in Osceola County and Orange County, Florida
by: Nick Taylor, et al.
Published: (2020-01-01)

Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
by: A. V. Rudakova, et al.
Published: (2016-02-01)

Cost utility analysis of antibiotics compared with operative treatment in uncomplicated acute appendicitis
by: Napaphat Poprom, et al.
Published: (2025-04-01)

Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran
by: Zahra Goudarzi, et al.
Published: (2025-03-01)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01)

Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis
by: Ryan J. Bamforth, et al.
Published: (2024-11-01)

Field therapies for actinic keratosis: an Australian cost‐effectiveness analysis
by: Yaron Gu, et al.
Published: (2025-03-01)

The cost of the diagnostic odyssey of patients with suspected rare diseases
by: Rick Glaubitz, et al.
Published: (2025-05-01)

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy
by: Valentina Perrone, et al.
Published: (2025-01-01)

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment
by: Barbara Polistena, et al.
Published: (2025-07-01)

Hepatitis B knowledge and stigma in the United Arab Emirates
by: Hiba Jawdat Barqawi, et al.
Published: (2025-03-01)

Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01)

Economic burden of hepatitis B patients and its influencing factors in China: a systematic review
by: Mengxia Yan, et al.
Published: (2024-11-01)

Cost Analysis and Waste Elimination in Efforts to Prepare Inpatient Room Rates as an Efficiency and Effectiveness Strategy in Managing a Hospital Business
by: Budhi Setianto, et al.
Published: (2025-03-01)

METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Healthcare Resource Use and Costs of Allogeneic Hematopoietic Stem Cell Transplantation Complications: A Scoping Review
by: Nancy V. Kim, et al.
Published: (2025-05-01)

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
by: Santiago Moreno Guillen, et al.
Published: (2017-09-01)

Colorectal cancer-related resource utilization and healthcare costs in Saudi Arabia
by: Bander Balkhi, et al.
Published: (2023-11-01)

Estimating Costs Associated with Adverse Events in Patients with Advanced Lung Cancer
by: Lin CY, et al.
Published: (2024-10-01)

Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19
by: Carolina Moreno, et al.
Published: (2025-07-01)

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
by: Rebecca Dean, et al.
Published: (2021-01-01)

‘FLEXIBLE’ BUDGETS ARE ALREADY BUDGETING PROCESS ANALYSIS OF PRODUCTION COSTS FOR OIL AND FAT ENTERPRISES
by: V. Shvetz’, et al.
Published: (2013-10-01)

Cost-effective interventions to prevent prescription drug misuse: a systematic review
by: L. Yesenia Rodríguez-Tanta, et al.
Published: (2025-03-01)

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain
by: Carlos Escobar, et al.
Published: (2025-07-01)

Cost-effectiveness and benefit-risk of rotavirus vaccination in Afghanistan: a modelling analysis informed by post-licensure surveillance
by: Palwasha Anwari, et al.
Published: (2025-07-01)

The effect of family physician program and health transformation plan on utilization and cost of health services
by: Zeynab Safarpoor, et al.
Published: (2025-06-01)

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
by: Robert J. Wong
Published: (2025-04-01)

Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C
by: I. A. Narkevich, et al.
Published: (2024-02-01)

INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
by: Mouna Jameleddine, et al.
Published: (2024-10-01)

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
by: A. V. Rudakova, et al.
Published: (2017-04-01)

Cost Development and Cost Drivers in UK Offshore Wind Farms
by: Sindre Lorentzen, et al.
Published: (2025-09-01)